

*Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.*

## **FOR IMMEDIATE RELEASE, September 10, 2001**

### **Immunex Expands Commercial Operation with New Sales Team**

Barry Labinger Appointed to Senior Vice President & General Manager, Scott Burton Joins Immunex as New Vice President of Sales for ENBREL® (etanercept)

\*\*\*

SEATTLE - Immunex Corporation [Nasdaq: IMNX] today announced that the company will expand its commercial operations with a new general manager overseeing the sales, marketing and development of franchises for both ENBREL® (etanercept) and Specialty Therapeutics.

Barry Labinger, vice president of marketing for ENBREL, has been promoted to senior vice president and general manager at the company. Since joining Immunex in June 2000, Labinger has led initiatives to build the franchise for ENBREL through the company's supply management program and other programs that have established the product's leadership position.

"Barry's core strength is pharmaceutical marketing that has helped establish strong brands," said Peggy Phillips, executive vice president and chief operating officer at Immunex. "His strong leadership skills and extensive experience will serve Immunex well as we position the company toward the goal of achieving multi-billion dollar revenue growth over the coming years."

To take advantage of growing demand for ENBREL and potential new uses for the product, the company announced that it will build its first Immunex sales force to sell ENBREL. This U.S. sales force will work with Wyeth-Ayerst, which has been selling ENBREL since its launch in 1998.

To lead the Immunex sales team, the company named Scott Burton as the new vice president of sales for ENBREL. Burton, who will join Immunex in mid-September, will be responsible for hiring and managing the new sales team.

"Scott is an exceptional individual who brings an impressive track record of commercial success," said Phillips. "We are excited to expand the presence of ENBREL in the marketplace with a sales team that will focus on key prescribers and potential new uses for the product."

Labinger has more than 14 years of healthcare industry experience, primarily in marketing and sales. Prior to joining Immunex, he oversaw the marketing for the U.S. diabetes franchise at Bristol-Myers Squibb, including GLUCOPHAGE®. He also previously worked at Abbott Laboratories and Baxter Healthcare Corporation. Labinger earned a Bachelor's degree with a major in Economics from Northwestern University and has a Masters of Management degree from the Kellogg School of Management at Northwestern University.

Burton has more than 14 years of experience in field sales and product management, including work in the managed care, cardiovascular and anti-infective markets. Most recently, he was business director of regional operations at Bristol-Myers Squibb where he oversaw a sales team of more than 130 people. He has also worked at Pfizer Laboratories. Burton earned a B.S. in Marketing from Utah State University.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

NOTE: *Except for the historical information contained herein, this news release contains forward-looking*

*statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements.*